Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/10305
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors
Bermejo, Mercedes ISCIII | Ambrosioni, Juan | Bautista, Guiomar | Climent, Núria | Mateos, Elena ISCIII | Rovira, Cristina | Rodriguez‑Mora, Sara ISCIII | Lopez-Huertas, Maria Rosa ISCIII | García-Gutiérrez, Valentín | Steegmann, Juan Luis | Duarte, Rafael | Cervantes, Francisco | Plana, Montserrat | Miró, José M | Alcamí, José ISCIII | Coiras, Mayte ISCIII
Biochem Pharmacol. 2018 Oct;156:248-264.
Current antiretroviral treatment (ART) may control HIV-1 replication but it cannot cure the infection due to the formation of a reservoir of latently infected cells. CD4+ T cell activation during HIV-1 infection eliminates the antiviral function of the restriction factor SAMHD1, allowing proviral integration and the reservoir establishment. The role of tyrosine kinases during T-cell activation is essential for these processes. Therefore, the inhibition of tyrosine kinases could control HIV-1 infection and restrict the formation of the reservoir. A family of tyrosine kinase inhibitors (TKIs) is successfully used in clinic for treating chronic myeloid leukemia (CML). The safety and efficacy against HIV-1 infection of five TKIs was assayed in PBMCs isolated from CML patients on prolonged treatment with these drugs that were infected ex vivo with HIV-1. We determined that the most potent and safe TKI against HIV-1 infection was dasatinib, which preserved SAMHD1 antiviral function and avoid T-cell activation through TCR engagement and homeostatic cytokines. Imatinib and nilotinib showed lower potency and bosutinib was quite toxic in vitro. Ponatinib presented similar profile to dasatinib but as it has been associated with higher incidence of arterial ischemic events, dasatinib would be the better choice of TKI to be used as adjuvant of ART in order to avoid the establishment and replenishment of HIV-1 reservoir and move forward towards an HIV cure.
Cell Proliferation | Cell Survival | HEK293 Cells | HIV-1 | Humans | Leukocytes, Mononuclear | Protein Kinase Inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Files in this item
- EvaluationOfResistanceToHIV_20 ...